Michael Lutz, managing director of Avalere, shares his prediction for the year.

A forecast for this year by Dan Parsons, chief experience officer of Thoughtful AI.

U.S. approved the RSVpreF vaccine for adults 60 years and older in 2023, recommending it only based on individual’s decisions with their doctors.

Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus continue to outweigh their risks.

Predictions for this year from Perry Cohen, Pharm.D., CEO of the TPG Family of Companies and Managed Healthcare Executive editorial advisory board member.

Predictions for 2025 by Tracy Baroni Allmon, J.D., vice president of Market Access and Policy at Magnolia Market Access.

A small study of 18 patients with skin cancer found that the combination of vitamin D and chemotherapy provided an immune response that lasted up to five years.

Blue Shield of California new CEO Lois Quam said she will focus on the challenges that members face with accessing healthcare.

Over 20 nonprofit veteran advocacy groups will receive $9 million over the next three years to address homelessness and mental health concerns in veterans.

A forecast for this year by Luis E. Taveras, Ph.D., senior vice president and chief information officer of Lehigh Valley Health Network.

A prediction for 2025 by Michael Meucci, president and CEO of Arcadia.

A prediction for this year from Jason Spangler, M.D., M.P.H., CEO, Center for Innovation & Value Research.

A new, first-of-its-kind study found that these symptoms occur particularly during the late menopause transition and post-menopause.

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice yearly investigational pre-exposure prophylaxis (PrEP) injection.

Effective Jan. 1, 2025, Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an accelerated approval based on a surrogate endpoint.

The 68-year-old Florida man is walking 106 miles from Key Largo to Key West.

Gastric cancer, commonly known as stomach cancer, is the fifth most common cancer globally and the fifth leading cause of cancer-related deaths.

The updated guidelines from the American Diabetes Association emphasize the use of antibody-based screening for type 1 diabetes and recommend that physicians discuss potential use of Tzield, a monoclonal antibody approved to delay the onset of the symptoms of the disease.

Modern research shows women’s health issues go beyond reproductive health and highlight women’s elevated risk for autoimmune and cardiovascular disease – among other conditions.

Few studies in this analysis assessed the accuracy of AI in detecting melanoma in diverse skin tones.

Here’s what you missed this week on Managed Healthcare Executive.

Conventional drug development typically zeroes in on individual proteins or signaling pathways. By focusing on the transcription factor FOXO3, Refoxy hopes to harness a key regulator that impacts numerous biological processes.

Regenerative medicine focuses on repairing damaged skin and bringing back melanocytes, the cells that give skin its color.

By narrowing their research to overweight and obese individuals, Roswell Park researchers found that metformin might offer benefits that previous trials overlooked.